Literature DB >> 21540188

Role of p38 protein kinase in the ligand-independent ubiquitination and down-regulation of the IFNAR1 chain of type I interferon receptor.

Sabyasachi Bhattacharya1, Juan Qian, Christos Tzimas, Darren P Baker, Constantinos Koumenis, J Alan Diehl, Serge Y Fuchs.   

Abstract

Phosphorylation-dependent ubiquitination and degradation of the IFNAR1 chain of type I interferon (IFN) receptor is a robust and specific mechanism that limits the magnitude and duration of IFNα/β signaling. Besides the ligand-inducible IFNAR1 degradation, the existence of an "inside-out" signaling that accelerates IFNAR1 turnover in the cells undergoing the endoplasmic reticulum (ER) stress and activated unfolded protein responses has been recently described. The latter pathway does not require either presence of ligands (IFNα/β) or catalytic activity of Janus kinases (JAK). Instead, this pathway relies on activation of the PKR-like ER kinase (PERK) and ensuing specific priming phosphorylation of IFNAR1. Here, we describe studies that identify the stress activated p38 protein kinase as an important regulator of IFNAR1 that acts downstream of PERK. Results of the experiments using pharmacologic p38 kinase inhibitors, RNA interference approach, and cells from p38α knock-out mice suggest that p38 kinase activity is required for priming phosphorylation of IFNAR1 in cells undergoing unfolded protein response. We further demonstrate an important role of p38 kinase in the ligand-independent stimulation of IFNAR1 ubiquitination and degradation and ensuing attenuation of IFNα/β signaling and anti-viral defenses. We discuss the distinct importance of p38 kinase in regulating the overall responses to type I IFN in cells that have been already exposed to IFNα/β versus those cells that are yet to encounter these cytokines.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21540188      PMCID: PMC3121351          DOI: 10.1074/jbc.M111.238766

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  52 in total

1.  Catalytically active TYK2 is essential for interferon-beta-mediated phosphorylation of STAT3 and interferon-alpha receptor-1 (IFNAR-1) but not for activation of phosphoinositol 3-kinase.

Authors:  M R Rani; D W Leaman; Y Han; S Leung; E Croze; E N Fish; A Wolfman; R M Ransohoff
Journal:  J Biol Chem       Date:  1999-11-05       Impact factor: 5.157

Review 2.  ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions.

Authors:  Philippe P Roux; John Blenis
Journal:  Microbiol Mol Biol Rev       Date:  2004-06       Impact factor: 11.056

3.  The search for physiological substrates of MAP and SAP kinases in mammalian cells.

Authors:  P Cohen
Journal:  Trends Cell Biol       Date:  1997-09       Impact factor: 20.808

4.  p38 MAP kinase is required for STAT1 serine phosphorylation and transcriptional activation induced by interferons.

Authors:  K C Goh; S J Haque; B R Williams
Journal:  EMBO J       Date:  1999-10-15       Impact factor: 11.598

5.  Type I interferon (IFN)-dependent activation of Mnk1 and its role in the generation of growth inhibitory responses.

Authors:  Sonali Joshi; Surinder Kaur; Amanda J Redig; Katy Goldsborough; Kevin David; Takeshi Ueda; Rie Watanabe-Fukunaga; Darren P Baker; Eleanor N Fish; Rikiro Fukunaga; Leonidas C Platanias
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-02       Impact factor: 11.205

6.  Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells.

Authors:  Simrit Parmar; Efstratios Katsoulidis; Amit Verma; Yongzhong Li; Antonella Sassano; Lakhvir Lal; Beata Majchrzak; Farhad Ravandi; Martin S Tallman; Eleanor N Fish; Leonidas C Platanias
Journal:  J Biol Chem       Date:  2004-03-31       Impact factor: 5.157

7.  Basal ubiquitin-independent internalization of interferon alpha receptor is prevented by Tyk2-mediated masking of a linear endocytic motif.

Authors:  K G Suresh Kumar; Bentley Varghese; Anamika Banerjee; Darren P Baker; Stefan N Constantinescu; Sandra Pellegrini; Serge Y Fuchs
Journal:  J Biol Chem       Date:  2008-05-12       Impact factor: 5.157

8.  Virus-induced unfolded protein response attenuates antiviral defenses via phosphorylation-dependent degradation of the type I interferon receptor.

Authors:  Jianghuai Liu; Wei-Chun HuangFu; K G Suresh Kumar; Juan Qian; James P Casey; Robert B Hamanaka; Christina Grigoriadou; Rafael Aldabe; J Alan Diehl; Serge Y Fuchs
Journal:  Cell Host Microbe       Date:  2009-01-22       Impact factor: 21.023

9.  Resistance to vesicular stomatitis virus infection requires a functional cross talk between the eukaryotic translation initiation factor 2alpha kinases PERK and PKR.

Authors:  Dionissios Baltzis; Li-Ke Qu; Stavroula Papadopoulou; Jaime D Blais; John C Bell; Nahum Sonenberg; Antonis E Koromilas
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

10.  Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: involvement of p38 MAPK and ERK.

Authors:  Masakazu Kono; Koichiro Tatsumi; Alberto M Imai; Kengo Saito; Takayuki Kuriyama; Hiroshi Shirasawa
Journal:  Antiviral Res       Date:  2007-11-20       Impact factor: 5.970

View more
  33 in total

Review 1.  Eliminative signaling by Janus kinases: role in the downregulation of associated receptors.

Authors:  Christopher J Carbone; Serge Y Fuchs
Journal:  J Cell Biochem       Date:  2014-01       Impact factor: 4.429

2.  Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment.

Authors:  Kanstantsin V Katlinski; Jun Gui; Yuliya V Katlinskaya; Angelíca Ortiz; Riddhita Chakraborty; Sabyasachi Bhattacharya; Christopher J Carbone; Daniel P Beiting; Melanie A Girondo; Amy R Peck; Ellen Puré; Priya Chatterji; Anil K Rustgi; J Alan Diehl; Constantinos Koumenis; Hallgeir Rui; Serge Y Fuchs
Journal:  Cancer Cell       Date:  2017-02-13       Impact factor: 31.743

3.  Suppression of Type I Interferon Signaling Overcomes Oncogene-Induced Senescence and Mediates Melanoma Development and Progression.

Authors:  Yuliya V Katlinskaya; Kanstantsin V Katlinski; Qiujing Yu; Angelica Ortiz; Daniel P Beiting; Angela Brice; Diwakar Davar; Cindy Sanders; John M Kirkwood; Hallgeir Rui; Xiaowei Xu; Constantinos Koumenis; J Alan Diehl; Serge Y Fuchs
Journal:  Cell Rep       Date:  2016-03-24       Impact factor: 9.423

4.  Type 1 interferons contribute to the clearance of senescent cell.

Authors:  Yuliya V Katlinskaya; Christopher J Carbone; Qiujing Yu; Serge Y Fuchs
Journal:  Cancer Biol Ther       Date:  2015-06-05       Impact factor: 4.742

5.  Expression of the IFNAR1 chain of type 1 interferon receptor in benign cells protects against progression of acute leukemia.

Authors:  Bin Zhao; Sabyasachi Bhattacharya; Qiujing Yu; Serge Y Fuchs
Journal:  Leuk Lymphoma       Date:  2017-05-15

6.  Type I interferons mediate pancreatic toxicities of PERK inhibition.

Authors:  Qiujing Yu; Bin Zhao; Jun Gui; Kanstantsin V Katlinski; Angela Brice; Yan Gao; ChangHong Li; Jake A Kushner; Constantinos Koumenis; J Alan Diehl; Serge Y Fuchs
Journal:  Proc Natl Acad Sci U S A       Date:  2015-12-01       Impact factor: 11.205

7.  An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular Vesicles.

Authors:  Angelica Ortiz; Jun Gui; Farima Zahedi; Pengfei Yu; Christina Cho; Sabyasachi Bhattacharya; Christopher J Carbone; Qiujing Yu; Kanstantsin V Katlinski; Yuliya V Katlinskaya; Simran Handa; Victor Haas; Susan W Volk; Angela K Brice; Kim Wals; Nicholas J Matheson; Robin Antrobus; Sonja Ludwig; Theresa L Whiteside; Cindy Sander; Ahmad A Tarhini; John M Kirkwood; Paul J Lehner; Wei Guo; Hallgeir Rui; Andy J Minn; Constantinos Koumenis; J Alan Diehl; Serge Y Fuchs
Journal:  Cancer Cell       Date:  2019-01-14       Impact factor: 31.743

8.  Anti-tumorigenic effects of Type 1 interferon are subdued by integrated stress responses.

Authors:  S Bhattacharya; W-C HuangFu; G Dong; J Qian; D P Baker; J Karar; C Koumenis; J A Diehl; S Y Fuchs
Journal:  Oncogene       Date:  2012-10-08       Impact factor: 9.867

9.  Therapeutic Elimination of the Type 1 Interferon Receptor for Treating Psoriatic Skin Inflammation.

Authors:  Jun Gui; Michael Gober; Xiaoping Yang; Kanstantsin V Katlinski; Christine M Marshall; Meena Sharma; Victoria P Werth; Darren P Baker; Hallgeir Rui; John T Seykora; Serge Y Fuchs
Journal:  J Invest Dermatol       Date:  2016-06-29       Impact factor: 8.551

Review 10.  Interferon receptor signaling in malignancy: a network of cellular pathways defining biological outcomes.

Authors:  Eleanor N Fish; Leonidas C Platanias
Journal:  Mol Cancer Res       Date:  2014-09-12       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.